Common Stock, par value of $0.0001 per share
- Symbol
- IMMX
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 8.01, 9.01 · 8-K
Immix Biopharma, Inc.
IMMXNASDAQEQUITYCurrent
Other Events
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit Description No. ──────────────────────────────────────────────────────────────────────────────────────────────────────────────────── 1.1 Underwriting Agreement, dated September 29, 2026, by and between Immix Biopharma, Inc. and J.P. Morgan Securities LLC. 5.1 Opinion of Blank Rome LLP. 23.1 Consent of Blank Rome LLP (included in Exhibit 5.1).…
Press release in this filing
Immix Biopharma Announces Pricing of $125 Million Underwritten Offering of Common Stock →Company context
Immix Biopharma, Inc. (ImmixBio) (Nasdaq: IMMX) is a global leader in AL Amyloidosis. AL Amyloidosis is a devastating disease where the immune system, that’s supposed to protect, instead produces toxic light chains, clogging up the heart, kidney and liver, causing organ failure and death. Our lead candidate is sterically-optimized BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy NXC-201 with a proprietary CD3ζ, CD8 hinge and binder “digital filter” designed to filter out non-specific activation. NXC-201 teaches the immune system to recognize and eliminate the source of the toxic light chains. NXC-201 is being evaluated in the U.S. multi-center study for relapsed/refractory AL Amyloidosis NEXICART-2 (NCT06097832), with a potentially registrational design. NXC-201 has been awarded Breakthrough Therapy Designation (BTD) and Regenerative Medicine Advanced Therapy (RMAT) by the US FDA and Orphan Drug Designation (ODD) by FDA and in the EU by the EMA.
Current securities
Registered securities in this filing
IMMIX BIOPHARMA, INC. · 8-K · Filed 2026-09-30
Disclosure sections
Item 9.01Item 9.01 - Financial Statements and Exhibits
Item
9.01 Financial Statements and Exhibits.
(d)
Exhibits.
Exhibit Description
No.
────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
1.1 Underwriting
Agreement, dated September 29, 2026,
by and between Immix Biopharma, Inc. and J.P. Morgan Securities LLC.
5.1 Opinion of Blank Rome LLP.
23.1 Consent of Blank Rome LLP (included in Exhibit 5.1).
99.1 Press Release, dated September 29, 2026.
104 Cover
Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document.
Filed exhibits (1)
Exhibit 99.1 Immix Biopharma Announces Pricing of $125 Million Underwritten Offering of Common Stock LOS ANGELES, CA, September 29, 2026 (GLOBE NEWSWIRE) - Immix Biopharma, Inc. (“ImmixBio”, “Company”, “we” or “us” or “IMMX”), a global leader in relapsed/refractory AL Amyloidosis, today announced the pricing of an underwritten registered offering of 11,363,637 shares of its common stock at a public offering price of $11.00 per share. The gross proceeds from this offering are expected to be $125 million, before deducting underwriting discounts and commissions and offering expenses payable by the Company. The offering is expected to close on or about September 30, 2026, subject to the satisfaction of customary closing conditions. Immix intends to use the net proceeds from this offering to fund NXC-201 development, working capital and general corporate purposes. J.P. Morgan is acting as the sole book-running manager for the offering. The offering included participation from new and existing institutional investors, including Eventide Asset Management, Janus Henderson Investors, Ridgeback Capital Investments L.P., Wellington Management and other leading U.S. biotechnology instituti…
Open exhibit ↗